A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, phase III study to evaluate efficacy and safety of HCP1803-4 in patients with essential hypertension
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
256
Donggguk University Ilsan Hospital
Goyang-si, Gyeonggi-do, South Korea
Change from baseline in sitting systolic blood pressure
Time frame: Baseline, 10 weeks
Change from baseline in sitting systolic blood pressure
Time frame: Baseline, 2 weeks, 6 weeks
Change from baseline in sitting diastolic blood pressure
Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks
Proportion of subjects achieving blood pressure control (sitSBP)
Time frame: 2 weeks, 6 weeks, 10 weeks
Proportion of subjects achieving blood pressure control (sitSBP, sitDBP)
Time frame: 2 weeks, 6 weeks, 10 weeks
Blood pressure response rate (sitSBP)
Time frame: 2 weeks, 6 weeks, 10 weeks
Blood pressure response rate (sitSBP, sitDBP)
Time frame: 2 weeks, 6 weeks, 10 weeks
Treatment response rate
Time frame: 2 weeks, 6 weeks, 10 weeks
Change from baseline in pulse pressure
Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Control drug